Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
Teen vaccination against meningococcal disease starts From mid-September, young people born between 1 May and 31 December 2004 will receive an invitation for a vaccination against meningococcal disease.
New method for toxicological assessment of perfluoro mixtures Perfluoro (PFAS) is a group of substances that contains PFOS, PFOA and GenX. Perfluoro substances often occur as pollution in ground water and drinking water.
Vaccination rate again drops slightly, HPV vaccination rate drops considerably The vaccination rate for vaccines included in the National Immunisation Programme has dropped slightly by about 1 percent.
Proposal for water quality standards for PFOA RIVM proposes water quality standards for perfluoro octanoic acid (PFOA). PFOA is a man-made chemical that is used to protect surfaces.
Risks of potential release of genetically modified mosquitoes evaluated On Saba, a Dutch Caribbean island, diseases such as dengue, chikungunya and zika can be reduced by the use of genetically modified mosquitoes.
RIVM and Olive Foundation open trading to mark the European Cervical Cancer Prevention Week January 20th, the Olive Foundation and RIVM opened AEX trading day in Amsterdam on the occasion of the 9th European Cervical Cancer Prevention Week.
The National Immunisation Programme in the Netherlands 2013 - 2014 Every year, RIVM provides an overview of surveillance and developments in the National Immunisation Programme (NIP).
RIVM involvement in UN/EU missions RIVM-experts from the Environmental Assessment Unit (EAU) have undertaken two missions involving an emergency situation in the Solomon Islands and an environmental assessment in Georgia.
Increasing number of girls immunised against HPV In 2014 the number of girls who were immunised against the human papilloma virus (HPV) rose. This virus can cause cervical cancer later in life.